These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21878539)

  • 1. SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter.
    van Kuilenburg AB; Largiadèr CR
    Clin Cancer Res; 2011 Sep; 17(17):5837; author reply 5835-6. PubMed ID: 21878539
    [No Abstract]   [Full Text] [Related]  

  • 2. SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.
    Opdam FL; Swen JJ; Wessels JA; Gelderblom H
    Clin Cancer Res; 2011 Sep; 17(17):5833-4; author reply 5835-6. PubMed ID: 21878541
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
    Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
    Rosmarin D; Palles C; Church D; Domingo E; Jones A; Johnstone E; Wang H; Love S; Julier P; Scudder C; Nicholson G; Gonzalez-Neira A; Martin M; Sargent D; Green E; McLeod H; Zanger UM; Schwab M; Braun M; Seymour M; Thompson L; Lacas B; Boige V; Ribelles N; Afzal S; Enghusen H; Jensen SA; Etienne-Grimaldi MC; Milano G; Wadelius M; Glimelius B; Garmo H; Gusella M; Lecomte T; Laurent-Puig P; Martinez-Balibrea E; Sharma R; Garcia-Foncillas J; Kleibl Z; Morel A; Pignon JP; Midgley R; Kerr D; Tomlinson I
    J Clin Oncol; 2014 Apr; 32(10):1031-9. PubMed ID: 24590654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility.
    Lee AM; Diasio RB
    J Clin Oncol; 2014 Apr; 32(10):989-90. PubMed ID: 24590640
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?
    Mercier C; Ciccolini J
    Trends Pharmacol Sci; 2007 Dec; 28(12):597-8. PubMed ID: 18001850
    [No Abstract]   [Full Text] [Related]  

  • 7. 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798).
    González-Perera I; Gutiérrez-Nicolás F; Nazco-Casariego GJ; Ramos-Díaz R; Hernández-San Gil R; Pérez-Pérez JA; González García J; González De La Fuente GA
    J Oncol Pharm Pract; 2017 Jul; 23(5):396-398. PubMed ID: 27122156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A; Rajebi MR; Harold L; Saif MW
    JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.
    Gentile G; Botticelli A; Lionetto L; Mazzuca F; Simmaco M; Marchetti P; Borro M
    Pharmacogenomics J; 2016 Aug; 16(4):320-5. PubMed ID: 26216193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
    Terrazzino S; Cargnin S; Del Re M; Danesi R; Canonico PL; Genazzani AA
    Pharmacogenomics; 2013 Aug; 14(11):1255-72. PubMed ID: 23930673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
    Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
    Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
    González-Haba E
    Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.
    Lazar A; Gründemann D; Schömig E
    Mol Diagn Ther; 2007; 11(5):341; author reply 341-2. PubMed ID: 17963423
    [No Abstract]   [Full Text] [Related]  

  • 18. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
    Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
    Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
    Ciccolini J; Mercier C; Dahan L; Evrard A; Boyer JC; Richard K; Dales JP; Durand A; Milano G; Seitz JF; Lacarelle B
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):272-5. PubMed ID: 16292536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.